Stock AnalizAddus HomeCare Corp ADUS
Medical/Nursing Services · IPO 2009 · data as of November 13, 2026
Addus HomeCare Corp (ADUS) is a healthcare company listed in the US with a market value of about $2.3B. In the twelve months to September 30, 2026 it had revenue of $1.5B and net income of $111M, a net margin of 7.4%.
Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 20.5, a price to free cash flow of 15.9, 5-year revenue growth of 13% a year, a 5-year average ROIC of 7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 18% below the current price.
Score: 3.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- 3-year free cash flow growth above 10% a year
- 5-year average ROIC above 12%
- ROE above 15%
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.4B | $1.2B | $1.1B | $951M | $864M | $765M | $649M | $517M | $426M | $401M |
| Net income | $111M | $96M | $74M | $63M | $46M | $45M | $33M | $25M | $16M | $12M | $12M |
| Free cash flow | $144M | $104M | $110M | $103M | $97M | $35M | $103M | $7M | $28M | $49M | -$2M |
| EPS (diluted) | $6.01 | $5.22 | $4.23 | $3.83 | $2.84 | $2.81 | $2.08 | $1.77 | $1.33 | $1.03 | $1.07 |
| Net margin | 7.4% | 6.7% | 6.4% | 5.9% | 4.8% | 5.2% | 4.3% | 3.9% | 3.2% | 2.8% | 3.0% |
| ROIC | — | 8.3% | 6.1% | 7.9% | 6.5% | 5.9% | 4.6% | 4.9% | 6.4% | 6.6% | 6.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $140.92, 15% above the current price; targets range from $101.00 to $160.00; the consensus rating is “Buy”; expected EPS is $7.08 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Addus HomeCare’s P/E ratio?
About 20.5, based on the last twelve months of diluted earnings per share (forward P/E about 16.6).
Is Addus HomeCare stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 18% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Addus HomeCare pay a dividend?
Not currently.
Is Addus HomeCare a good stock to buy?
We do not give buy or sell advice. Addus HomeCare scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.